Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

383 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High circulating SDF-1and MCP-1 levels and genetic variations in CXCL12, CCL2 and CCR5: Prognostic signature of immune recovery status in treated HIV-positive patients.
Yeregui E, Viladés C, Domingo P, Ceausu A, Pacheco YM, Veloso S, Inciarte A, Vidal-González J, Peraire M, Perpiñán C, Falcó V, Masip J, Alba V, Vargas M, Martí A, Reverté L, Mallolas J, Vidal F, Peraire J, Rull A. Yeregui E, et al. Among authors: mallolas j. EBioMedicine. 2020 Dec;62:103077. doi: 10.1016/j.ebiom.2020.103077. Epub 2020 Nov 6. EBioMedicine. 2020. PMID: 33166788 Free PMC article.
Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study).
Ribera E, Azuaje C, Lopez RM, Domingo P, Soriano A, Pou L, Sánchez P, Mallolas J, Sambea MA, Falco V, Ocaña I, Lopez-Colomes JL, Gatell JM, Pahissa A. Ribera E, et al. Among authors: mallolas j. J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):317-23. doi: 10.1097/01.qai.0000182629.74336.4d. J Acquir Immune Defic Syndr. 2005. PMID: 16249706 Clinical Trial.
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.
Mallolas J, Podzamczer D, Milinkovic A, Domingo P, Clotet B, Ribera E, Gutiérrez F, Knobel H, Cosin J, Ferrer E, Arranz JA, Roca V, Vidal F, Murillas J, Pich J, Pedrol E, Llibre JM, Dalmau D, García I, Aranda M, Cruceta A, Martínez E, Blanco JL, Lazzari Ed, Gatell JM; ATAZIP Study Group. Mallolas J, et al. J Acquir Immune Defic Syndr. 2009 May 1;51(1):29-36. doi: 10.1097/QAI.0b013e31819a226f. J Acquir Immune Defic Syndr. 2009. PMID: 19390327 Clinical Trial.
Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis.
Lejeune M, Miró JM, De Lazzari E, García F, Claramonte X, Martínez E, Ribera E, Arrizabalaga J, Arribas JR, Domingo P, Ferrer E, Plana M, Valls ME, Podzamczer D, Pumarola T, Jacquet A, Mallolas J, Gatell JM, Gallart T; Spanish Toxoplasma gondii Study Group. Lejeune M, et al. Among authors: mallolas j. Clin Infect Dis. 2011 Mar 1;52(5):662-70. doi: 10.1093/cid/ciq197. Clin Infect Dis. 2011. PMID: 21292671
Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants.
Vidal F, López-Dupla M, Laguno M, Veloso S, Mallolas J, Murillas J, Cifuentes C, Gallart L, Auguet T, Sampériz G, Payeras A, Hernandez P, Arnedo M, Gatell JM, Richart C. Vidal F, et al. Among authors: mallolas j. PLoS One. 2012;7(11):e47725. doi: 10.1371/journal.pone.0047725. Epub 2012 Nov 2. PLoS One. 2012. PMID: 23133602 Free PMC article. Clinical Trial.
383 results